Concentra, Inc. Third Quarter 2026 Earnings Call - CONCENTRA GROUP HOLDINGS PARENT INC

Financial Performance:

• Total revenue grew 8.6% year-over-year to $622.1 million, with organic growth accelerating slightly to 8.6% from 8.0% in Q2.
• Net income increased 36% YoY to $67.8 million ($0.52 per share); adjusted net income rose 33.3% to $66.1 million.
• Adjusted EBITDA reached $140.2 million, up 17.9% YoY, with margin expanding 178 basis points to 22.5%.
• Segment revenue growth: Occupational health centers +8.3% ($569.7M), Workers' compensation +7.9% ($370.5M), Employer services +10% ($190.5M), On-site +10% ($38.4M), Other +18.4% ($14.1M).
• Cost of services improved to 68.6% of revenue (down from 70.8% prior year) due to visit/rate growth and staffing efficiencies.
• Operating cash flow was $51.9 million (down from $60.6M YoY) due to working capital timing and tax payments; Free Cash Flow was $32.2 million.
• Balance sheet: Net leverage ratio stood at 2.90x; total debt $1.52 billion; cash balance $85.8 million.
• Capital returns: Repurchased 1 million shares ($34.65M) and paid $8M in dividends; new $250M share repurchase authorization granted post-quarter.

Guidance and Future Outlook:

• Raised 2026 revenue guidance to $2.36 billion–$2.38 billion (increased low end by $35M, high end by $5M).
• Lowered 2026 adjusted EBITDA guidance to $505 million–$510 million (decreased low end by $20M, high end by $15M).
• Maintained 2026 free cash flow guidance ($220M–$240M) and capital expenditure guidance ($70M–$80M).
• Formal 2027 guidance expected early next year; currently expect employer services rate growth of ~3% and stable workers' comp rates pending state fee schedule announcements.
• 2026 center expansion: 15 new centers expected via acquisitions and DeNovo openings; anticipating low double-digit DeNovo openings in 2027.
• Debt reduction remains a priority, targeting a long-term net leverage ratio of 2.5x over the next 12 months.

Business Segments and Product Lines:

• Patient visits per day averaged >58,000 (+4.9% YoY), driven by +4.2% growth in workers' comp and +5.8% in employer services.
• Revenue per visit increased 3.3% YoY (workers' comp +3.5%, employer services +4.0%), influenced by favorable mix shifts toward higher-revenue physicals.
• Recent acquisitions: Four medical centers in Minnesota; recent DeNovo openings in Kansas City, Boise, Daytona Beach, Pensacola, and Washington D.C.
• New markets: Entry into Boise and Daytona Beach represents new geographic expansions.
• On-site business fundamentals remain strong, supported by healthcare cost management trends and integration benefits.
• Customer retention at multi-year highs; new business activity tracking ahead of 2025 levels.

Market and Competitive Landscape:

• Growth is broad-based across all six regions and most end markets, fueled by favorable blue-collar labor conditions.
• Market share gains are occurring due to strong sales execution, account management, and technology investments.
• Reshoring trends and data center build-outs are showing early signs of demand in manufacturing and logistics, though currently immaterial to overall revenue.
• New York market entry under review; regulatory changes (E&M code increases) deemed attractive for potential DeNovo or bolt-on acquisition entry expected early 2027.
• Company ratings improved: S&P upgraded from BB- to BB; Moody's outlook changed from stable to positive.

Risks and Challenges:

• Workers' compensation rate growth is dependent on state fee schedule announcements; most states have not yet released 2027 schedules.
• Labor market dynamics (wage inflation, clinician availability) remain a monitoring focus; current turnover is stable with ~3% wage inflation.
• New York regulatory timeline uncertainty regarding the new proposal implementation.
• Potential volatility in visit mix (drug screens vs. physicals) affecting employer services revenue per visit in the short term.

Management Commentary and Tone:

• Call marked the leadership transition to CEO Matt DiCanio and CFO Tanner Newton (effective Nov 1), with Keith Newton remaining as Executive Chairman.
• Tone is confident and positive, citing "considerable strength," "proven strategy," and "disciplined execution."
• Management emphasized successful completion of separation activities with Select Medical and the transition to a standalone entity.
• Confidence expressed in sustaining current margin levels, though year-over-year expansion may moderate compared to 2026.

Analyst Questions and Answers:

• Visit Metrics: Q3 visits driven by initial injury volume rather than increased visits per patient; complexity trends remain high.
• M&A Modeling: Analysts advised to model only definitive M&A deals, not unannounced transactions, for 2027.
• New York Expansion: Regulatory decision expected early 2027; rate increases make entry viable via DeNovo or acquisition.
• Rate vs. Mix: Employer services rate growth (4%) partially driven by mix shift to physicals; workers' comp (3.5%) driven primarily by fee schedule gains.
• Reshoring/Data Centers: Trends are positive but currently immaterial; monitoring 300+ projects with a focus on construction sector growth.
• Election Impact: No immediate material impact expected; growth remains broad-based across industries and geographies.
• G&A Run Rate: Q3 G&A included one-time separation costs; expected run rate will sit between Q2 and Q3 levels as costs stabilize.
• Margin Sustainability: Management expects to sustain current margin levels; significant year-over-year expansion unlikely without further operational leverage.
• Capital Allocation: Priorities remain accretive growth (organic/inorganic), debt paydown to 2.5x leverage, and share repurchases.
• Employer Services Lag: Historically a leading indicator for workers' comp volumes; currently one quarter of data, requiring continued monitoring.
• DeNovo Economics: Payback period estimated at 2–3 years; ramp-up strategies involve aggressive pre-opening sales and marketing to secure anchor accounts.

Other Key Points:

• Successful separation from Select Medical concluded with the expiration of the Transition Services Agreement (TSA) at month-end.
• Acquisitions of competitors and DeNovo development continue to fuel the 15-center 2026 growth target.
• Strong cash flow generation supports simultaneous debt reduction, growth investments, and shareholder returns.